Skip to content

Oruka Therapeutics, Inc. ORKA Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
Amgen logo
AmgenAMGN
-$8M-104%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$3.57M+228%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.92M+102%
Alumis Inc. logo
Alumis Inc.ALMS
$545K+1,334%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$11.73M+257%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s change in other assets?
Oruka Therapeutics, Inc. (ORKA) reported change in other assets of $60K in Q1 2025.
What is the long-term trend for Oruka Therapeutics, Inc.'s change in other assets?
Over 2 years (2021 to 2023), Oruka Therapeutics, Inc.'s change in other assets has grown at a 0.0% compound annual growth rate (CAGR), from $6K to -$6K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.